Skip to main content
AAN.com
Brief Communications
May 1, 1987

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease
A 5‐year follow‐up

May 1987 issue
37 (5) 826

Abstract

Compared with levodopa, long-term bromocriptine treatment of parkinsonian patients for 5 years resulted in fewer fluctuations of disability and peak-dose dyskinesias, but also less improvement in parkinsonian disability. Combination of low-dose bromocriptine and levodopa resulted in a therapeutic response equal to that of levodopa alone but with fewer end-of-dose disturbances and peak-dose dyskinesias. I believe that treatment should begin promptly with a low dose of levodopa, combined with a dopamine agonist such as bromocriptine.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Neurology®
Volume 37Number 5May 1987
Pages: 826
PubMed: 3574685

Publication History

Published online: May 1, 1987
Published in print: May 1987

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

U. K. Rinne, MD
Department of Neurology, University of Turku, Turku, Finland.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Quinpirole inhibits levodopa-induced dyskinesias at structural and behavioral levels: Efficacy negated by co-administration of isradipine, Experimental Neurology, 369, (114522), (2023).https://doi.org/10.1016/j.expneurol.2023.114522
    Crossref
  2. Novel therapeutic interventions for combating Parkinson’s disease and prospects of Nose-to-Brain drug delivery, Biochemical Pharmacology, 195, (114849), (2022).https://doi.org/10.1016/j.bcp.2021.114849
    Crossref
  3. Copper-Catalyzed Direct C(sp 3 )–H Alkoxylation to Access Quaternary α-Alkoxylated Amino Acid Derivatives , Organic Letters, 22, 15, (5796-5800), (2020).https://doi.org/10.1021/acs.orglett.0c01853
    Crossref
  4. Treatment of Parkinson's disease, Postgraduate Medicine, 95, 5, (52-69), (2017).https://doi.org/10.1080/00325481.1994.11945830
    Crossref
  5. Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l -Dopa, Parkinson's Disease, (295-343), (2017).https://doi.org/10.1016/bs.irn.2017.01.006
    Crossref
  6. Parkinson's Disease, Journal of Pharmacy Practice, 6, 6, (283-289), (2016).https://doi.org/10.1177/089719009300600605
    Crossref
  7. Effects of Bromocriptine on Dopamine Turnover with or without Levodopa, Journal of International Medical Research, 24, 3, (271-277), (2016).https://doi.org/10.1177/030006059602400306
    Crossref
  8. Oral dopamine agonists in the management of Parkinson's disease, Parkinson's Disease, (34-47), (2016).https://doi.org/10.1017/CBO9781107284210.005
    Crossref
  9. The Pharmacological Basis for Parkinson's Disease Treatment, Parkinson's Disease, (1-92), (2016).https://doi.org/10.1017/CBO9781107284210.001
    Crossref
  10. Back to the tubule: microtubule dynamics in Parkinson’s disease, Cellular and Molecular Life Sciences, 74, 3, (409-434), (2016).https://doi.org/10.1007/s00018-016-2351-6
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Share article link

Share